Member of Lyonbiopole
KUSTE Biopharma is a clinical-stage biotechnology company founded by seasoned life sciences entrepreneurs. KUSTE develops molecules for severe chronic inflammatory diseases.
The company’s lead indication is Interstitial Cystitis also called Bladder Pain Syndrome (IC/BPS). Brimapitide, a small penetrating peptide, JNK inhibitor, demonstrated to be safe and effective in large patient pool, has been developed for IC/BPS in a Phase 2a. KUSTE is now launching Phase 2b. Among other indications we are developing Ulcerative Colitis now in Pre-clinical, preparing for Phase 1/2a.
Strategic application domain: Human Medicine
Application market: Urology
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Others
Created on june 5th, 2019 - 5 employees
Address
Tour Part-Dieu, 129 rue Servient 69326 Lyon Lyon cedex 3
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.